Sei Investments Co. Has $237,000 Stock Position in Axonics, Inc. (NASDAQ:AXNX)

Sei Investments Co. lessened its position in shares of Axonics, Inc. (NASDAQ:AXNX - Free Report) by 89.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,533 shares of the company's stock after selling 30,064 shares during the quarter. Sei Investments Co.'s holdings in Axonics were worth $237,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in AXNX. Headlands Technologies LLC increased its position in shares of Axonics by 31.1% in the 1st quarter. Headlands Technologies LLC now owns 1,117 shares of the company's stock valued at $77,000 after buying an additional 265 shares in the last quarter. Whittier Trust Co. lifted its holdings in shares of Axonics by 59.1% during the 1st quarter. Whittier Trust Co. now owns 1,142 shares of the company's stock valued at $79,000 after purchasing an additional 424 shares in the last quarter. Inspirion Wealth Advisors LLC acquired a new position in shares of Axonics in the 1st quarter valued at approximately $207,000. Janney Montgomery Scott LLC bought a new stake in Axonics during the 1st quarter worth approximately $218,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Axonics during the 1st quarter worth approximately $285,000. Institutional investors own 99.48% of the company's stock.

Analysts Set New Price Targets

Separately, Needham & Company LLC restated a "hold" rating on shares of Axonics in a report on Monday, August 5th. Eight research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, Axonics currently has an average rating of "Hold" and a consensus price target of $69.57.

Insiders Place Their Bets

In other Axonics news, CFO Kari Leigh Keese sold 2,961 shares of Axonics stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total value of $205,523.01. Following the completion of the sale, the chief financial officer now owns 40,362 shares in the company, valued at $2,801,526.42. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.85% of the company's stock.

Axonics Stock Performance

Shares of AXNX remained flat at $70.30 during mid-day trading on Friday. The stock had a trading volume of 592,874 shares, compared to its average volume of 733,580. The stock has a market cap of $3.59 billion, a PE ratio of -1,757.06 and a beta of 0.82. Axonics, Inc. has a 52 week low of $48.30 and a 52 week high of $70.53. The business's fifty day moving average price is $69.11 and its 200-day moving average price is $68.11.

Axonics (NASDAQ:AXNX - Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.03. The firm had revenue of $114.57 million during the quarter, compared to analysts' expectations of $112.83 million. Axonics had a negative net margin of 0.42% and a negative return on equity of 0.27%. The company's revenue for the quarter was up 23.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.15) earnings per share. As a group, research analysts predict that Axonics, Inc. will post 0.24 EPS for the current fiscal year.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.